NDA 017765 · Legacy
Cloderm
Clocortolone Pivalate · Topical
NovelLast checked: Nov 20, 2026Latest source record: May 21, 2009 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1977
Aug 22, 1977
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2
0 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 22, 1977 Original approval · Type 1 - New Molecular Entity
1 products under this application
- CLODERM · CLOCORTOLONE PIVALATE 0.1% · CREAM, TOPICAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Clocortolone Pivalate" as an intervention, any sponsor and status, largest first.
- Bio-equivalence Vasoconstriction Activity Study for Topically Applied Clocortolone Pivalate 0.1% CreamPivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT04358770 · 124 participants · Start Mar 2, 2018 · Primary completion Apr 27, 2018
Drug: Clocortolone Pivalate · For: Bioequivalence Study
Sites: Dallas, Texas
Promius Pharma, LLCIndustry
NCT01714544 · 60 participants · Start Oct 2012 · Primary completion Mar 2013
Drug: Cloderm Cream · For: Psoriasis
Sites: Cincinnati, Ohio; Portland, Oregon; Austin, Texas · 5 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cloderm (Clocortolone Pivalate)
2024 spending
$5K
Beneficiaries
n/a
13 claims
Per beneficiary
n/a
$8.05 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $96,063 |
| 2021 | $107,021 |
| 2022 | $43,812 |
| 2023 | $30,735 |
| 2024 | $4,707 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Adherence to clocortolone pivalate cream 0.1% in a pediatric population with atopic dermatitis.
Conde JF, Kaur M, Fleischer AB, et al. · Cutis 2008 · Clinical Trial, Comparative Study
- Clocortolone pivalate: a paired comparison clinical trial of a new topical steroid in eczema/atopic dermatitis.
Rosenthal AL · Cutis 1980 · Clinical Trial, Comparative Study
- A study to assess the occlusivity and moisturization potential of three topical corticosteroid products using the skin trauma after razor shaving (STARS) bioassay.
Kircik LH · J Drugs Dermatol 2014 · Comparative Study, Controlled Clinical Trial
- Clocortolone pivalate cream 0.1% used concomitantly with tacrolimus ointment 0.1% in atopic dermatitis.
Torok HM, Maas-Irslinger R, Slayton RM · Cutis 2003 · Clinical Trial, Comparative Study
- The treatment of inflammatory facial dermatoses with topical corticosteroids: focus on clocortolone pivalate 0.1% cream.
Kircik LH, Del Rosso JQ · J Drugs Dermatol 2012 · Clinical Trial
- Safety and efficacy of clocortolone pivalate 0.1 percent cream in the treatment of atopic dermatitis, contact dermatitis, and seborrheic dermatitis.
Nierman MM · Cutis 1981 · Clinical Trial, Review
Sponsor: Legacy
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.